SNX-2112
SNX-2112 是一种热休克蛋白 90 (Hsp90) 抑制剂，具有抗癌特性，目前正在临床试验中。SNX-2112 通过 Akt/mTOR/p70S6K 抑制途径以时间和剂量依赖的方式诱导自噬。SNX-2112 在人类黑色素瘤 A-375 细胞中诱导显著的凋亡和自噬，可能是一种有效的靶向治疗药物。
顾客使用 Adooq 产品发表的高质量科研文献
Adooq用户使用SNX-2112发表的2篇文献
生物活性
| Discription | SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor with anticancer properties currently in clinical trials. SNX-2112 induced autophagy in a time- and dose-dependent manner via Akt/mTOR/p70S6K inhibition. SNX-2112 induces significant apoptosis and autophagy in human melanoma A-375 cells, and may be an effective targeted therapy agent |
|||||
|---|---|---|---|---|---|---|
| Targets |
|
|||||
| Cell Research |
|
产品信息
| 目录号 | A11189 |
|---|---|
| 分子式 | C23H27F3N4O3 |
| 分子量 | 464.48 |
| CAS号 | 908112-43-6 |
| SMILES | CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)O)C(F)(F)F)C |
| 其他名称 | SNX2112, PF 04928473 |
| 储存条件 | Store lyophilized at -20ºC, keep desiccated. |
溶解性数据
| In vitro (25°C) | DMSO | 90 mg/mL (193.76 mM) | |
| Water | Insoluble | ||
| Ethanol | 1 mg/mL (2.15 mM) | ||
| In vivo | 0.5% CMC+0.25% Tween 80 | 28 mg/mL | |
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
Preparing Stock Solutions
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 21.53 mL | 107.65 mL | 215.29 mL |
| 0.5 mM | 4.31 mL | 21.53 mL | 43.06 mL |
| 1 mM | 2.15 mL | 10.76 mL | 21.53 mL |
| 5 mM | 0.43 mL | 2.15 mL | 4.31 mL |
Useful Calculator
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
Keywords: 购买 SNX-2112 | SNX-2112 供应商 | SNX-2112 花费 | SNX-2112 生产商 | 订购 SNX-2112 | SNX-2112 代理商
| 购买 908112-43-6 | 908112-43-6 供应商 | 908112-43-6 花费 | 908112-43-6 生产商 | 订购 908112-43-6 | 908112-43-6 代理商